Ohtuvayre (Ensifentrine) - What is Ensifentrine?

Ohtuvayre (Ensifentrine) - Ensifentrine is a drug used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that has selective dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibition. COPD is a group of diseases that primarily cause airflow obstruction and breathing problems, including emphysema and chronic bronchitis. Ohtuvayre improves patients' respiratory function through the combined action of a bronchodilator and a nonsteroidal anti-inflammatory drug.

The U.S. Food and Drug Administration (FDA's approval of Ohtuvayre was based on extensive clinical data, including the Phase 3 clinical trials ENHANCE-1 and ENHANCE-2. These trials showed that exefentine not only significantly improved lung function when used alone, but also demonstrated promising clinical benefit when combined with other maintenance therapies. Research results show that Ohtuvayre can effectively improve lung function, and its improvement effect is statistically and clinically significant.

Ohtuvayre is available as an inhalation suspension that can be delivered directly to the lungs via a standard jet nebulizer. Its use does not require patients to have high inspiratory flow rates or complex hand-breathing coordination, making its use more convenient. In addition, doctors and patients need to pay attention to possible warnings and precautions when using Ohtuvayre, including possible paradoxical bronchospasm and psychiatric adverse reactions.

In clinical application, some common adverse reactions have also been reported, such as back pain, high blood pressure, urinary tract infection and diarrhea. The incidence rates of these side effects are greater than or equal to 1%, and they are more common than the placebo group. Doctors need to fully consider these potential adverse reactions when prescribing to ensure the safety and effectiveness of treatment for patients.

Overall,Ohtuvayre, as a new type of COPD treatment drug, provides a new treatment option for the majority of patients with chronic obstructive pulmonary disease with its unique mechanism of action and significant therapeutic effect.

Reference materials:https://fanyi.sogou.com/text?keyword=&transfrom=auto&transto=zh-CHS&model=general